TY  - JOUR
AU  - Padilla-Galo, A
AU  - García-Ruiz, A J
AU  - Levy Abitbol, R Ch
AU  - Olveira, C
AU  - Rivas-Ruiz, F
AU  - García-Agua Soler, N
AU  - Pérez Morales, M
AU  - Valencia Azcona, B
AU  - Tortajada-Goitia, B
AU  - Moya-Carmona, I
AU  - Levy-Naon, A
PY  - 2021
DO  - 10.1186/s12931-021-01758-0
UR  - http://hdl.handle.net/10668/17842
T2  - Respiratory research
AB  - Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after...
LA  - en
KW  - Asthma
KW  - Benralizumab
KW  - Biologics
KW  - Cost-effectiveness
KW  - Economic impact
KW  - Eosinophils
KW  - Real-life
KW  - Severe asthma
KW  - Anti-Asthmatic Agents
KW  - Antibodies, Monoclonal, Humanized
KW  - Asthma
KW  - Cost-Benefit Analysis
KW  - Cross-Sectional Studies
KW  - Disease Progression
KW  - Drug Costs
KW  - Female
KW  - Follow-Up Studies
KW  - Forced Expiratory Volume
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Patient Acuity
KW  - Treatment Outcome
TI  - Real-life cost-effectiveness of benralizumab in patients with severe asthma.
TY  - research article
VL  - 22
ER  -